By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Pfizer says patient dies after receiving hemophilia drug in trial - 2UAE recalls some Nestle infant formula products, Qatar warns consumers
- 3Help Your Efficiency: 10 Authoritative Apparatuses to Attempt
- 4Watch Blue Origin's huge New Glenn rocket ace its epic landing on a ship at sea (video)
- 5Vote in favor of the Web-based Work out schedule to Keep You Fit and Sound
- Israel’s mixed messaging on Christmas draws controversy
- ‘Democratizing space’ is more than just adding new players – it comes with questions around sustainability and sovereignty
- 'Home Alone' actor Joe Pesci said 'no' to this stunt until he saw a 9-year-old girl do it, says director Chris Columbus
- Israel strikes south Lebanon after first direct talks in decades
- 5 Critical Rules For Business Regulation Chiefs
- Hezbollah claims right to respond to killing of top commander
- Addressing sleep apnea early might decrease chances of developing Parkinson's disease
- Everyday Seasonal Positions That Compensate Fairly in the US
- NASA loses contact with its Maven spacecraft orbiting Mars for the past decade
